Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) alterations, encompassing gene amplification, mutation, and protein overexpression, are identified in 2-3% of nonsquamous non-small cell lung cancer (NSCLC) (1). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.